TLT Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$26,530.00
Insider Selling (Last 12 Months): C$0.00

Theralase Technologies Insider Trading History Chart

This chart shows the insider buying and selling history at Theralase Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Theralase Technologies Share Price & Price History

Current Price: C$0.32
Price Change: Price Decrease of -0.005 (-1.54%)
As of 12/9/2022 06:23 PM ET

This chart shows the closing price history over time for TLT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Theralase Technologies Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2022Roger John Dumoulin-WhiteDirectorBuy32,000C$0.32C$10,240.007,576,387
4/6/2022Roger John Dumoulin-WhiteDirectorBuy20,000C$0.32C$6,300.007,544,387
12/16/2021Roger John Dumoulin-WhiteDirectorBuy33,300C$0.30C$9,990.007,524,387
10/1/2021Roger John Dumoulin-WhiteDirectorBuy50,000C$0.20C$10,000.007,491,087
9/22/2021Kristina Maria HacheySenior OfficerBuy50,000C$0.20C$10,000.001,756,267
9/10/2021Roger John Dumoulin-WhiteDirectorBuy45,000C$0.22C$9,900.007,441,087
5/4/2021Roger John Dumoulin-WhiteDirectorBuy50,000C$0.21C$10,500.007,396,087
5/3/2021Kristina Maria HacheySenior OfficerBuy90,000C$0.22C$19,800.001,706,267
4/30/2021Arkady MandelSenior OfficerBuy60,000C$0.24C$14,100.0060,000
4/19/2021Roger John Dumoulin-WhiteDirectorBuy65,500C$0.25C$16,375.007,341,587
2/25/2021Roger John Dumoulin-WhiteDirectorBuy10,000C$0.28C$2,800.007,276,087
2/17/2021Roger John Dumoulin-WhiteDirectorBuy30,500C$0.25C$7,625.007,266,087
1/28/2021Roger John Dumoulin-WhiteDirectorBuy45,500C$0.22C$10,010.007,235,587
1/18/2021Guy John AndersonDirectorBuy27,777C$0.18C$4,999.86213,777
9/25/2020Roger John Dumoulin-WhiteDirectorBuy33,000C$0.16C$5,280.007,190,087
9/15/2020Roger John Dumoulin-WhiteDirectorBuy29,000C$0.17C$4,930.007,157,087
7/31/2020Roger John Dumoulin-WhiteDirectorBuy62,500C$0.16C$10,000.007,128,087
7/22/2020Roger John Dumoulin-WhiteDirectorBuy48,000C$0.21C$10,080.007,065,587
6/15/2020Roger John Dumoulin-WhiteDirectorBuy43,500C$0.23C$10,005.007,017,587
6/2/2020Roger John Dumoulin-WhiteDirectorBuy40,000C$0.25C$10,000.006,974,087
5/1/2020Roger John Dumoulin-WhiteDirectorBuy48,000C$0.21C$10,080.006,934,087
4/22/2020Roger John Dumoulin-WhiteDirectorBuy60,000C$0.18C$10,500.006,886,087
4/8/2020Roger John Dumoulin-WhiteDirectorBuy45,400C$0.22C$9,988.006,826,087
4/1/2020Roger John Dumoulin-WhiteDirectorBuy2,500C$0.18C$450.006,780,687
3/17/2020Roger John Dumoulin-WhiteDirectorBuy53,000C$0.19C$10,070.006,778,187
2/18/2020Roger John Dumoulin-WhiteDirectorBuy38,500C$0.26C$10,010.006,725,187
1/28/2020Roger John Dumoulin-WhiteDirectorBuy34,000C$0.30C$10,030.006,686,687
12/19/2019Roger John Dumoulin-WhiteDirectorBuy32,500C$0.32C$10,400.006,652,687
See Full Table

SEC Filings (Institutional Ownership Changes) for Theralase Technologies (CVE:TLT)

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.
Read More on Theralase Technologies

Today's Range

Now: C$0.32
Low: C$0.32
High: C$0.32

50 Day Range

MA: C$0.27
Low: C$0.24
High: C$0.34

52 Week Range

Now: C$0.32
Low: C$0.23
High: C$0.48

Volume

26,000 shs

Average Volume

140,640 shs

Market Capitalization

C$69.28 million

P/E Ratio

N/A

Dividend Yield

2.03%

Beta

N/A

Who are the company insiders with the largest holdings of Theralase Technologies?

Theralase Technologies' top insider shareholders include:
  1. Roger John Dumoulin-White (Director)
  2. Kristina Maria Hachey (Senior Officer)
  3. Guy John Anderson (Director)
  4. Arkady Mandel (Senior Officer)
Learn More about top insider investors at Theralase Technologies.